Xiidra vs Vabysmo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Xiidra | US Vabysmo | |
|---|---|---|
| Generic name | lifitegrast | faricimab |
| Drug class | LFA-1 Antagonist (Eye Drop) | VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) |
| Treats | Dry eye disease | Wet macular degeneration, diabetic macular edema |
| Category | Eye Health | Eye Health |
| Manufacturer | Bausch + Lomb | Genentech (Roche) |
| Year approved | 2016 | 2022 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $150M | $85M |
| Common side effects | Eye irritation, Unusual taste, Blurred vision, Eye discomfort on application | Eye inflammation, Floaters, Increased eye pressure, Blurred vision |
Frequently asked questions
Is Xiidra or Vabysmo better?
Neither is universally "better." Xiidra (lifitegrast) and Vabysmo (faricimab) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Xiidra and Vabysmo?
Xiidra is a LFA-1 Antagonist (Eye Drop) made by Bausch + Lomb, while Vabysmo is a VEGF/Ang-2 Bispecific Inhibitor (Eye Injection) made by Genentech (Roche). See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Xiidra has the larger estimated TV advertising budget of the two.